Section 4: Clinical Pharmacy Services

4CPS-095

DRUG-DRUG INTERACTIONS AMONG HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS

4CPS-094

IMPROVING CHRONIC HEPATITIS B VIRUS OUTCOMES USING A WEB AND SMARTPHONE-BASED MEDICATION SELF-MANAGEMENT PLATFORM

4CPS-086

PROPOSAL TO DARUNAVIR (DRV) THE LEAST TROUGH PLASMA LEVEL (TPL) CUT-OFF TO ESTIMATE PLASMA HIV VIRAL LOAD (HVL) EQUAL OR LESS THAN 20 COPIES/ML

4CPS-081

COMPARISON OF THE COCKCROFT–GAULT, MDRD AND CKD–EPI EQUATIONS FOR ESTIMATING GANCICLOVIR CLEARANCE

4CPS-077

DO WE NEED TO ADOPT ANTIFUNGAL STEWARDSHIP PROGRAMMES?

4CPS-076

EVALUATION OF THE TREATMENT AND MORBIMORTALITY OF INFECTIOUS ENDOCARDITIS BY STAPHYLOCOCCUS AUREUS

4CPS-075

COMPLIANCE OF A PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS PROTOCOL IN CARDIAC SURGERY

4CPS-070

ANTIMICROBIAL STEWARDSHIP TEAM: MANAGEMENT OF PIPERACILIN/TAZOBACTAM SUPPLY SHORTAGE

4CPS-066

PHARMACEUTICAL INTERVENTIONS IN A THIRD-LEVEL HOSPITAL

4CPS-053

IMPROVEMENT OPPORTUNITIES IN THE USE OF ANTIMICROBIALS

4CPS-047

USE OF VANCOMYCIN: CURRENT PRACTICES IN A PAEDIATRIC HOSPITAL

4CPS-044

GROWTH HORMONE THERAPY FOLLOW-UP PROGRAMME IN PAEDIATRIC PATIENTS

4CPS-042

APREMILAST IN PSORIATIC ARTHRITIS AND PSORIASIS: A CASE REPORT

4CPS-040

COST-COMPARISON OF SECUKINUMAB AND USTEKINUMAB FOR TREATMENT OF PSORIASIS

4CPS-039

ALLANTOIN 6% CREAM IN EPIDERMOLYSIS BULLOSA: A CASE REPORT

Pages